Healthcare Industry News: cannabinoid
News Release - April 4, 2018
Abide Therapeutics Appoints Thomas C. Südhof to Board of DirectorsSAN DIEGO, April 4, 2018 -- (Healthcare Sales & Marketing Network) -- Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes with an emphasis on CNS disorders, announced today the appointment of Thomas Südhof to its Board of Directors. Prof. Südhof serves as Avram Goldstein Professor and Director of the Center for Cellular and Molecular Translational Neuroscience at Stanford School of Medicine. He is also an Investigator of the Howard Hughes Medical Institute, and a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. His current work focuses on two areas of neuroscience: the mechanisms that organize the presynaptic release machinery that mediates secretion of neurotransmitters during synaptic transmission, and the molecular organization of the trans-synaptic signaling machinery that enables synapse formation and specifications as well as synaptic plasticity. Prof. Südhof received the Nobel Prize in Physiology or Medicine for his work in neurophysiology. He is also a Director for Sanofi.
"We are delighted to welcome Tom to the Abide Board of Directors. His extensive works and deep expertise in neuroscience will be a tremendous asset to Abide," said Alan Ezekowitz, MBChB, D.Phil., President and CEO of Abide Therapeutics. "We are confident that his unique insights will play a key role in shaping our strategy in advancing our first-in-class pipeline, which has broad potential in CNS disorders."
"As a member of the Abide Scientific Advisory Board for the last year, I have seen the outstanding innovative work that is being done at Abide," said Prof. Südhof. "Given the potential of the work to transform the lives of patients with CNS disorders, I am excited to deepen my commitment to Abide by joining the Board of Directors, and to further help progress their efforts towards developing transformative medicines."
About Abide Therapeutics
Abide Therapeutics is focused on developing first-in-class drugs for serious diseases with significant unmet medical need. An innovative discovery platform and a library of proprietary small molecules allow Abide to address biological pathways with therapeutics that enhance the body's normal physiological response to disease. The platform enables Abide to efficiently identify, modify, and validate small-molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide's initial area of focus is on addressing neurological disorders with limited treatment options through the endocannabinoid pathway.
Abide has offices in San Diego, California and Princeton, New Jersey. To learn more, visit www.abidetx.com.
Source: Abide Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.